20 Fat-Loss Compounds Ranked Worst
to Best (No GLP-1s)
From a Phase 1 trial that ended in kidney toxicity to the FDA-approved gold standard for visceral fat — a complete tier-list breakdown of 20 non-GLP-1 fat-loss compounds circulating in peptide and biohacking research communities, with mechanism, dosing, and safety flags for every single one.
閱讀中文版 →This Tier List, At a Glance
S-Tier (gold standard)Tesamorelin, HGH, Albuterol
F-Tier (avoid)Adipotide (FTP), HGH Frag 176-191
Biggest red flagCardarine (GW501516) — rodent cancer signal
ScopeExcludes GLP-1 agonists (semaglutide, tirzepatide, retatrutide) entirely
Section 01
What This Ranking Is — and Isn't
This article summarizes and organizes a single research-community tier-list ranking of 20 non-GLP-1 fat-loss compounds — deliberately excluding semaglutide, tirzepatide, retatrutide, and other GLP-1 agonists, which are covered in our GLP-1 Comparison Guide. It is not a clinical practice guideline, a validated head-to-head comparison, or medical advice. Several compounds discussed below lack human clinical data entirely, and at least two carry documented, serious safety concerns that we flag explicitly rather than downplay.
Every compound below is tagged with an evidence level:
Clinical / human data Pre-clinical / rodent data Research-community / anecdotal
Why this matters: The central risk in this space is conflating efficacy with safety. A compound can show real fat-loss effects in rodents or early trials and still be a poor strategic choice — Adipotide is the clearest example below. Ranking position reflects a risk-to-reward judgment, not just raw effect size.
Section 02
The Complete Tier List: All 20 Compounds at a Glance
| Tier | Compound | Classification | Flag |
|---|---|---|---|
| S | Tesamorelin | GHRH analog | FDA-approved, visceral fat |
| S | HGH | Peptide hormone | Extensive clinical data |
| S | Albuterol | Beta-2 agonist | FDA-approved since 1981 |
| A | Mirabegron | Beta-3 agonist | FDA-approved (overactive bladder) |
| A | ATX-304 (OS-1) | Pan-AMPK activator | Small human trials |
| A | SLU-PP-332 | ERR agonist | Strong rodent data |
| A | BAM15 | Mitochondrial uncoupler | Rodent data |
| A | 5-Amino-1MQ | NNMT inhibitor | Rodent data |
| A | MOTS-c | Mitochondrial-derived peptide | Community field reports |
| A | CJC-1295 (No DAC) & Ipamorelin | GHRH / ghrelin mimetic | Community standard |
| B | Cardarine (GW501516) | PPARδ agonist | ⚠ Rodent cancer signal |
| B | IGF-1 LR3 | Growth factor | Anecdotal protocols |
| B | Kagrilintide | Amylin analog | ⚠ 50% anhedonia reported |
| B | SS-31 | Mitochondrial peptide | Cost-prohibitive |
| B | Tesofensine | Triple monoamine reuptake inhibitor | Phase 3 data, high side-effect rate |
| C | Setmelanotide | MC4R agonist | ⚠ Severe side effects |
| C | Sermorelin | GHRH | Outclassed, first-gen |
| D | AOD9604 | Modified HGH fragment | Marginal efficacy |
| F | HGH Frag 176-191 | Peptide fragment | No meaningful human data |
| F | Adipotide (FTP) | Pro-apoptotic peptide | ⚠ Renal toxicity in Phase 1 |
Section 03
Tier-by-Tier Breakdown
Starting from the bottom: the compounds that present an unacceptable risk-to-reward ratio, either from severe toxicity or a near-total absence of efficacy relative to modern alternatives.
FF-Tier — Avoid
Either severe systemic toxicity or effectively no efficacy advantage over simpler alternatives.
Adipotide (FTP)Phase 1 clinical data
Pro-apoptotic peptide
MechanismBinds prohibitin on adipose endothelium, triggering apoptosis by collapsing blood supply (ischemia) to fat cells.
Ranking logicPromising rodent/primate pre-clinical data, but Phase 1 human trials revealed no biological "off-switch" for the vascular effect.
DosingSubcutaneous — specific dosing omitted in source material due to documented toxicity.
Critical risk: dose-dependent renal (kidney) toxicity during clearance; ablates adipose vasculature indiscriminately regardless of remaining fat mass. This is why Adipotide is ranked at the bottom despite real pre-clinical efficacy — a clear case of efficacy without an acceptable safety margin.
HGH Fragment 176-191Anecdotal ranking
Peptide fragment
MechanismA specific segment of the HGH sequence marketed for fat-burning.
Ranking logicFrequently confused with full HGH but lacks systemic benefits, meaningful human data, and the improved stability of its derivative, AOD9604.
Side effectsNegligible — the core issue is non-efficacy, not toxicity.
DD-Tier — Marginal Efficacy
Some clinical backing, but effects too small to be a meaningful primary driver of fat loss.
AOD9604Phase 2 clinical data
Modified HGH fragment (tyrosine-modified for stability)
Ranking logicClinical trials showed only ~2 kg of fat loss above placebo over 12 weeks. Its main practical value is reducing water retention from other GH-related peptides, not direct lipolysis.
Dosing250 mcg – 1 mg daily, subcutaneous.
Side effectsGenerally well tolerated.
CC-Tier — Functional but Outclassed
Pharmacologically active, but superseded by agents with better potency or safety profiles.
SermorelinEstablished pharmacology
Growth Hormone Releasing Hormone (GHRH)
MechanismStimulates endogenous pituitary GH release.
Ranking logicA reliable "first-generation" GHRH peptide, but outclassed by Tesamorelin's precision or the CJC-1295/Ipamorelin combination's synergy.
Dosing250 mcg subcutaneous daily, at bedtime.
SetmelanotideFDA-approved, Phase 3
MC4R agonist
MechanismRestores satiety signaling via the leptin-melanocortin pathway.
Ranking logicHighly effective for appetite suppression in specific FDA-approved genetic obesity populations, but side effects make it impractical for general research use.
Dosing250 mcg (experimental) up to 3 mg (FDA dose), subcutaneous.
Notable side effects: severe nausea, skin hyperpigmentation, spontaneous erections, and depression are all documented in its FDA labeling.
BB-Tier — Specialized Use Cases
Rarely primary fat-loss drivers; used strategically for synergy, side-effect management, or specific sub-goals.
TesofensinePhase 3 trial data
Triple monoamine reuptake inhibitor (SNDRI)
MechanismInhibits reuptake of serotonin, norepinephrine, and dopamine; increases resting energy expenditure.
Ranking logicA "wild card" neurological agent — roughly 70% of users report results, but around 20% report significant adverse neurological effects.
Dosing250–500 mcg oral daily.
Side effects: insomnia, anxiety, dry mouth, elevated heart rate and blood pressure.
SS-31Clinical observation
Mitochondrial peptide
MechanismRepairs mitochondrial structural integrity rather than acting as a direct lipolytic agent.
Ranking logicCreates a "favorable metabolic environment" via mitochondrial repair; use is often limited by cost rather than efficacy.
Dosing1–10 mg subcutaneous daily.
KagrilintideClinical trial data
Amylin analog
MechanismSlows gastric emptying and acts on central satiety independently of GLP-1 receptors.
Ranking logicDiscussed as synergistic when stacked with GLP-1 agonists, allowing lower doses of each — but the psychiatric side-effect rate is a significant caution.
Dosing250 mcg – 4 mg subcutaneous weekly.
Notable risk: GI distress, and a reported ~50% incidence of anhedonia/depression in trial contexts discussed in the source material — a figure that warrants serious weight in any risk assessment.
IGF-1 LR3Anecdotal protocols
Muscle-building growth factor
MechanismPromotes muscle cell proliferation and body recomposition.
Ranking logicUsed as a lean-mass "toning" tool during caloric deficits, typically limited to short 4–6 week cycles.
Dosing25–200 mcg intramuscular, pre/post-workout.
Risk: hypoglycemia — requires immediate carbohydrate co-ingestion.
Cardarine (GW501516)Phase 2 + rodent data
PPARδ agonist
MechanismShifts metabolism toward fatty acid oxidation; substantially improves cardiovascular endurance.
Ranking logicFat loss here is largely indirect, via enhanced exercise performance and endurance rather than direct lipolysis.
Dosing10–20 mg oral daily, 4–8 week cycles (as discussed in source material).
Critical risk: rodent studies linked Cardarine to rapid oncogenesis (cancer development), which is why its original human trials were halted. This is a serious, documented safety concern — not a settled question — and is the single biggest red flag on this entire list.
AA-Tier — High-Value Metabolic Agents
"Workhorse" compounds offering robust metabolic benefits with generally manageable side-effect profiles.
CJC-1295 (No DAC) & IpamorelinResearch-community standard
GHRH analog / ghrelin mimetic combination
MechanismSynergistically increases endogenous growth hormone pulses. See our CJC-1295 and Ipamorelin monographs for full detail.
Ranking logicWidely discussed as an "entry-level" route to GH-based fat-loss research, offering many benefits associated with exogenous HGH at lower cost.
Dosing150–300 mcg subcutaneous.
Side effectsFlushing, water retention, occasional sleep disruption.
MOTS-cCommunity field reports
Mitochondrial-derived peptide
MechanismDescribed as an "exercise mimetic," improving mitochondrial efficiency and glucose uptake. See our MOTS-c monograph.
Ranking logicValued for metabolic flexibility and sustained energy rather than acute lipolysis.
Dosing1–2 mg subcutaneous daily.
Risk: potential hypoglycemia if carbohydrate intake is insufficient.
5-Amino-1MQRodent data
NNMT inhibitor
MechanismIncreases intracellular NAD+, reversing metabolic dysfunction inside fat cells. See our 5-Amino-1MQ monograph.
Ranking logicDiscussed for reducing fat-cell size without necessarily reducing food intake.
Dosing1–2 mg injectable, or 50–150 mg oral daily.
Risk: metabolic fatigue/burnout reported at high doses.
BAM15Rodent data
Mitochondrial uncoupler
MechanismDissipates the mitochondrial proton gradient, burning fuel as heat rather than storing it.
Ranking logicDiscussed as substantially safer than historical uncouplers like DNP; animal-model data suggests it may outperform GLP-1s in fat loss without lean-mass loss — human data is still limited.
Dosing50–100 mg oral daily, 8-week cycles (source material).
SLU-PP-332Strong rodent data
ERR (estrogen-related receptor) agonist
MechanismActivates genetic programs associated with endurance exercise and mitochondrial biogenesis. See our SLU-PP-332 monograph.
Ranking logicDiscussed as a premier "exercise mimetic" for fat oxidation and performance.
Dosing250–750 mcg subcutaneous or transdermal.
Risk: potential metabolic fatigue.
ATX-304 (OS-1)Small human trials
Pan-AMPK activator
MechanismActivates AMPK in skeletal muscle and liver; does not cross the blood-brain barrier.
Ranking logicDistinguished by early human data showing fat loss with muscle preservation — increasingly discussed as a maintenance tool after stopping GLP-1 therapy.
Dosing300–500 mg daily.
MirabegronFDA-approved, human studies
Selective beta-3 adrenergic agonist
MechanismActivates brown adipose tissue (BAT) thermogenesis via UCP1.
Ranking logicAn FDA-approved overactive-bladder medication repurposed in research contexts for BAT activation and metabolic health markers.
Dosing50 mg oral daily (FDA label dose).
Side effects: tachycardia and urinary retention.
SS-Tier — The Non-GLP-1 Gold Standard
The compounds with the most extensively documented human impact on body composition — the primary strategic alternatives to GLP-1 therapy.
AlbuterolFDA-approved since 1981
Beta-2 adrenergic agonist
MechanismDirectly increases lipolysis and resting energy expenditure (roughly 3–5%).
Ranking logicDecades of human safety data as an asthma medication; considerably more muscle-sparing than Clenbuterol.
Dosing2–5 mg oral daily, 2 weeks on / 2 weeks off (source material).
Caution: tremors, anxiety, and tachycardia are common; injecting Albuterol — especially combined with Yohimbine — creates a severe risk of acute tachycardia and cardiovascular distress.
HGH (Human Growth Hormone)Extensive clinical/FDA data
Peptide hormone
MechanismDirect GH receptor activation; upregulates hormone-sensitive lipase.
Ranking logicDiscussed as the long-term transformation tool — consistently shifting body composition toward fat loss and lean mass over 6–24 months.
Dosing1–4 IU subcutaneous daily.
Side effects: joint pain, water retention, and insulin resistance at higher doses.
TesamorelinPhase 3, FDA-approved
GHRH analog
MechanismStimulates pulsatile GH release, specifically targeting visceral adipose tissue (VAT).
Ranking logicRanked as the top non-GLP-1 peptide — the only one on this list with Phase 3 human data specifically for visceral fat reduction.
Dosing1–2 mg subcutaneous daily.
Notes: potential water retention; blood glucose monitoring is recommended.
Section 04
Research vs. Anecdote: Why the Distinction Matters
The gap between "clinically validated" and "field-reported" is the single most important lens for evaluating any compound on this list — predictability and known side-effect profiles differ enormously between the two categories.
| Evidence Type | Example Compounds | What It Means |
|---|---|---|
| Clinical (human) | Tesamorelin, Albuterol, ATX-304, Setmelanotide | High predictability; established human side-effect profiles. |
| Pre-clinical (rodent) | BAM15, 5-Amino-1MQ, SLU-PP-332 | Robust animal data; human safety and efficacy remain speculative. |
| Research-community / anecdotal | MOTS-c, CJC-1295/Ipamorelin, SS-31, IGF-1 LR3 | Rely on field reports; results and long-term human safety data are limited. |
The strategic takeaway: Adipotide demonstrated real pre-clinical fat-loss efficacy — and still ranks last, because its human-trial toxicity outweighs that efficacy entirely. A compound's tier position here reflects a risk-to-reward judgment, not a simple efficacy ranking. Prioritizing compounds with a documented human safety margin over raw pre-clinical effect size is the more defensible research posture.
FAQ
Frequently Asked Questions
What is the best non-GLP-1 fat loss compound?
This is a research-community opinion, not an established clinical ranking. In the tier list discussed here, Tesamorelin, HGH, and Albuterol occupy the top (S) tier — each has decades of human data (Albuterol, HGH) or Phase 3 trial data specific to visceral fat reduction (Tesamorelin). "Best" depends heavily on the research goal: visceral fat targeting, lean mass preservation, or resting energy expenditure each favor a different compound.
Is Cardarine (GW501516) safe?
This is a significant open safety question, not a settled one. Cardarine showed favorable lipid and endurance effects in short-term human trials, but rodent studies linked it to rapid oncogenesis (cancer development), which is why its original human trials were halted. Research-community discussion treats this as a critical risk flag rather than a resolved safety profile.
What happened with Adipotide (FTP) and why is it ranked so low?
Adipotide (also called FTP) showed promising pre-clinical fat-loss results in rodent and primate models by inducing apoptosis in the blood supply to fat tissue. However, Phase 1 human trials revealed dose-dependent renal (kidney) toxicity and no biological "off-switch" for the vascular effect, which is why it is generally ranked as a strategic failure despite pre-clinical promise.
Are peptides like MOTS-c and 5-Amino-1MQ backed by human research?
It varies by compound. Some, like 5-Amino-1MQ and SLU-PP-332, currently have strong rodent/pre-clinical data with human evidence still developing. Others, like MOTS-c and CJC-1295/Ipamorelin, are primarily supported by research-community field reports rather than large controlled human trials. This distinction matters for interpreting claimed effects and should not be conflated with FDA-approved, clinically validated compounds like Tesamorelin or Setmelanotide.
Explore the Full Compound Encyclopedia
CJC-1295, Ipamorelin, MOTS-c, 5-Amino-1MQ, and SLU-PP-332 all have full Monograph pages — mechanism, dosage tables, and creator citations.
Browse the Encyclopedia →